← Back to Search

CAR T-cell Therapy

Observational Cohort 1 for Acute Myeloid Leukemia

N/A
Recruiting
Research Sponsored by Vor Biopharma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has received any part of or all of a VOR33 infusion
Timeline
Screening 3 weeks
Treatment Varies
Follow Up years 1-15
Awards & highlights

Summary

VOR33 long-term follow-up (LTFU) study

Eligible Conditions
  • Acute Myeloid Leukemia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~years 1-15
This trial's timeline: 3 weeks for screening, Varies for treatment, and years 1-15 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Long term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs).
Secondary outcome measures
Long term efficacy of VOR33 in patients who participated in a VOR33 study in terms of persistence of CD33-negative hematopoiesis, overall survival (OS), and monthly relapse free survival (RFS).

Trial Design

1Treatment groups
Experimental Treatment
Group I: Observational Cohort 1Experimental Treatment1 Intervention
All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.

Find a Location

Who is running the clinical trial?

Vor BiopharmaLead Sponsor
2 Previous Clinical Trials
48 Total Patients Enrolled
~24 spots leftby Jan 2040
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top